![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, February 02, 2022 11:35:51 AM
"Big bio-opportunity: Sean, CEO of $GASE, Perasky is with Curadox.
Last time Sean and Perasky did a merger .40 to $3
This time, 8 million float"
"Curadox Biopharma, Inc. (CBI) will develop its
first product, CB-TD1, as a minimally toxic
treatment for ovarian cancer. CB-TD-1 has
already shown compelling results in in vitro
testing performed by the National Cancer Institute"
The incoming CFO is James Pekarsky. He is the former CEO of NYSE American-listed BioPharmX. SCM Capital helped do an offering and last year BioPharmX merged with the private company Timber Pharmaceuticals with 20 million in funding"
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM